Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KLTO

Klotho Neurosciences Inc

Feb 06 • 04:00PM ET

0.2402

+0.0195 8.84 %

Healthcare • Biotechnology • USA • NASD

Peers: CNC HUM MOH CI HCA UNH MCK HQY EVH GH

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.33	Insider Own	10.68%	Shs Outstand	70.33M	Perf Week	-11.40%
Market Cap	17.66M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	65.68M	Perf Month	-29.00%
Enterprise Value	10.31M	PEG	-	EPS next Q	-	Inst Own	4.13%	Short Float	0.60%	Perf Quarter	-49.13%
Income	-11.29M	P/S	-	EPS this Y	-	Inst Trans	3.78%	Short Ratio	0.54	Perf Half Y	-74.50%
Sales	0.00M	P/B	1.70	EPS next Y	-	ROA	-180.10%	Short Interest	0.39M	Perf YTD	-16.89%
Book/sh	0.14	P/C	2.40	EPS next 5Y	-	ROE	-198.28%	52W High	3.91 -93.86%	Perf Year	-33.28%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	-921.21% -	ROIC	-113.73%	52W Low	0.11 111.63%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.71% 9.65%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-53.57%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	83.69	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	32.05	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	83.69	EPS Q/Q	72.53%	SMA20	-19.42%	Beta	2.53	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-32.36%	Rel Volume	0.83	Prev Close	0.22
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	-60.55%	Avg Volume	724.41K	Price	0.24
IPO	Apr 29, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	600,743	Change	8.84%

Jan-08-26 08:00AM	Klotho Neurosciences to Present at the Biotech Showcase 2026 (PR Newswire)
Nov-07-25 10:03AM	Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award (PR Newswire)
Oct-16-25 08:00AM	Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston (PR Newswire) -6.26%
Oct-07-25 06:20PM	Klotho Neurosciences Announces Expiration of Letter of Intent (PR Newswire) +14.27%
Oct-01-25 05:33AM	Klotho to acquire Turn Biotechnologies assets (Pharmaceutical Technology)
08:30AM	Loading…
Sep-30-25 08:30AM	Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership (PR Newswire)
Sep-08-25 08:00AM	Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar (PR Newswire)
Aug-18-25 08:30AM	Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market (PR Newswire) -8.58%
Aug-12-25 06:00AM	Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology (PR Newswire)
Jul-25-25 09:05PM	UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology (PR Newswire) -8.13%
Jul-24-25 01:30PM	Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology (PR Newswire)
Jul-22-25 10:21AM	Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets (PR Newswire) +12.50%
Jul-16-25 06:00AM	Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules (PR Newswire) -5.19%
Jul-10-25 05:00AM	Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease") (PR Newswire) +6.57%
Jun-30-25 02:00AM	Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS (PR Newswire) +56.92%
05:00AM	Loading…
Jun-24-25 05:00AM	Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population (PR Newswire) +20.00%
Jun-18-25 07:00AM	KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS (PR Newswire)
Jun-16-25 07:00AM	KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT (PR Newswire)
Jun-09-25 07:00AM	KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("a-KLOTHO") (PR Newswire) +787.80%
07:00AM	KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("-KLOTHO") (PR Newswire)
Jan-08-25 11:00AM	Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco (GlobeNewswire) -8.94%
Dec-09-24 11:00AM	Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board (GlobeNewswire)
Dec-03-24 11:00AM	Former Merck USA President Joins Klotho Neurosciences' Board of Directors (GlobeNewswire)
Oct-23-24 06:00AM	Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor (GlobeNewswire) -18.57%
Oct-15-24 06:00AM	Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences (GlobeNewswire)
Sep-30-24 06:00AM	Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO) (GlobeNewswire) -10.95%
Sep-29-24 08:30PM	Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO) (GlobeNewswire)
Sep-17-24 06:30AM	ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc. (GlobeNewswire) +27.82%
Sep-04-24 07:46AM	Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy (GlobeNewswire) -8.39%
Aug-26-24 05:00AM	ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility (GlobeNewswire)
05:00AM	Loading…
Aug-21-24 05:00AM	ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ( TTS ) (GlobeNewswire) +15.53%
Aug-19-24 05:00AM	ANEW MEDICAL, INC. Appoints New CFO (GlobeNewswire)
Aug-15-24 05:00AM	ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases (GlobeNewswire) +11.00%
Aug-09-24 05:00AM	ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides (GlobeNewswire)
Aug-08-24 05:00AM	ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer's Disease and ALS (GlobeNewswire) +17.43%
Jul-09-24 08:09AM	Why Is Anew Medical (WENA) Stock Up 51% Today? (InvestorPlace) +17.24%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
05:30AM	ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments (GlobeNewswire)
Jun-27-24 05:00AM	ANEW MEDICAL Forms Strategic Partnership with Japan's Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene (GlobeNewswire) -17.13%
Jun-26-24 05:00AM	ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein (GlobeNewswire) +119.39%

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLTO

Klotho Neurosciences Inc

Upgrade your FINVIZ experience